Colossal Biosciences is growing chickens in a 3D-printed artificial eggshell

The baby chicks were shifting and starting to pip—or trying to hatch. But not from an egg. 

Instead, these chickens were growing inside transparent 3D-printed plastic cups at the Dallas headquarters of Colossal Biosciences.

The biotech company today claimed it has developed a “fully artificial egg” as part of its effort to resurrect extinct avian species, including birds like the dodo and the giant moa.

But “artificial eggshell” would probably be a better description for the invention. It’s an oval-shaped printed lattice, coated inside with a special silicone-based membrane that lets in oxygen, just as a real eggshell does. 

To generate birds, Colossal took recently laid chicken eggs and carefully poured their contents into the artificial shells, where they continued growing. A window on top lets researchers peek inside.  

“To see them all moving around in their artificial eggs was absolutely mind blowing,” says Andrew Pask, the company’s chief biology officer. “You really feel you can grow life outside of the womb.”

Colossal was founded in 2021 with plans to use gene editing and reproductive technology to restore extinct species, including the woolly mammoth. It’s since raised more than $800 million toward what it now terms the “scalable and controllable” creation of animals.

According to Pask, the egg technology could help conserve at-risk bird species. It could also play a role in a project to re-create the extinct giant moa, a flightless 12-foot-tall bird that once lived in New Zealand and laid four-liter eggs, larger than those of any living bird.

But Colossal may be able build one that’s big enough. The company provided a photograph of a prototype 3D-printed egg so large that staff have started to call it the “salad spinner.”

The moa went extinct after canoes carrying the ancestors of the Maori arrived on New Zealand’s South Island about 750 years ago. Archeological sites showcase the birds’ bones alongside stone cutting tools—clear evidence that they were hunted.

To be clear—Colossal isn’t close to re-creating the moa. Before that could happen, scientists would need to study DNA data from old moa bones and insert thousands of genetic changes into the genome of an existing bird, something that’s still technically difficult to do—with or without an artificial egg.

artificial womb for chicken embryos

COLOSSAL BIOSCIENCES

Some scientists also think Colossal is taking too much credit for its artificial eggshell, which it announced in a thundering YouTube video intoning that the company has solved the “impossible question of which came first, the chicken or the egg.”

The video is pure Hollywood—it’s meant to be funny and exciting. But Colossal has a habit of antagonizing scientists by making false and exaggerated claims. Last year, for instance, the company said it had re-created the extinct dire wolf—a claim widely rejected by experts. 

This time, Colossal’s fluffed-up assertion of having created the “first-ever shell-less incubation system” is what’s raising hackles among the small flock of scientists who’ve been working on the technology for years. 

“Clearly an overstatement,” says Katsuya Obara, at the University of Tsukuba in Japan, who in 2024 hatched chickens from beneath transparent plastic film. “The technology here is essentially a modification of existing methods.”

In fact, Obara notes, growing birds in artificial containers goes all the way back to 1998, when another Japanese group managed to do it with quail.

What may be an advance by Colossal is the special membrane, which lets the embryo access more oxygen. Previous systems required scientists to supplement the gas—something that may not have been good for the chicks, as often some of them would fail to hatch. 

The work on the artificial eggshell was carried out in Dallas by Colossal’s exogenous development team, or Exo Dev. That group is also trying to develop artificial wombs for mammals, starting with marsupials.

“We’re looking at every single facet of what’s happening during a mammalian pregnancy to unpack exactly how we then go about recapitulating that,” says Pask.

For that team, an artificial eggshell is a relatively quick and easy technical win. That’s because chickens are already an example of ex utero development. After an egg is laid, a small embryo sitting on top of the yolk starts growing, drawing nutrients from the yolk, the white, and even the shell, which provides calcium. (Colossal says it has to add ground-up calcium to the artificial eggs.)

looking down into the artificial egg shell to see a developing chick embryo and its vascular structure

COLOSSAL BIOSCIENCES

In order to create a moa, Colossal will have to genetically alter another type of bird, changing potentially thousands of DNA letters. But so far, chickens are the only bird species that can be genetically engineered. And that’s via a tricky process of editing stem cells that produce egg and sperm. Scientists have to add or delete DNA letters from these cells and then inject them back into an egg. The resulting bird will carry the genetic changes in its gonads—and then be able to pass them on. 

Pask says Colossal’s idea is that it could modify avian stem cells enough to produce moa-like sperm or eggs. But then you might have the odd situation of a chicken laying an egg with a moa embryo inside it. “You would have chickens making moa egg and moa sperm. But it’s still a chicken egg,” he says.

Helen Sang, a professor emeritus at the Roslin Institute in the United Kingdom, says she’s not sure a moa embryo could survive on the yolk of a chicken egg, given evolutionary differences. “There are significant challenges to overcome to grow an embryo of a different species in artificial eggs,” says Sang.

Just one of those is the huge size discrepancy. The amount of yolk in a chicken egg would hardly be enough to support the much larger moa chick. Yet Pask says that is exactly where the artificial egg will come in handy.

He says it may be possible to use a fine needle to slowly “put 50 yolks together to make that yolk mass much larger.”

“The chicken egg isn’t going to be big enough to support the growth of the moa through to term, to when it would normally hatch, but that’s when you could then take that egg, put it into the artificial egg environment, and then scale it up in size,” he says.

So far, Pask says, the artificial egg is working well for chickens—almost too well. “We hatched 26 chickens and then [our CEO] asked us to put the brakes on. We have too many chickens running around.”

Metaverse-Based Virtual Reality for Remote Anatomy Education: Pilot Randomized Controlled Trial

Background: Traditional anatomy teaching relies on cadaveric dissection and 2D resources, which often require in-person attendance and may limit spatial understanding. Virtual reality (VR) provides an immersive, remote alternative that supports 3D visualization from home. Recent evidence suggests that while VR may yield comparable factual knowledge gains to 2D methods, its primary value lies in enhancing learner engagement, motivation, and perceived educational value. Objective: This pilot randomized controlled trial compares remote synchronized VR with didactic animated anatomy lectures for the teaching of tracheostomy anatomy. Methods: Participants were recruited via convenience sampling through the VRiMS (Virtual Reality in Medicine and Surgery) Surgical Society network. All participants first attended a synchronous 20-minute online lecture delivered by a consultant surgeon. They were then individually randomized to one of 2 groups using a computer-generated sequence. Allocation was concealed until the intervention; however, participants and researchers were unblinded. The intervention group completed a 10-minute metaverse-based VR session, delivered by a consultant surgeon via 3D Organon’s Medverse platform on the PICO 4 Ultra headset. The control group completed a 10-minute prerecorded 2D animated lecture, accessed on their personal device. Participants then swapped to the other modality. Data were collected via Google Forms at 3 intervals (baseline, postintervention, and postcrossover) to assess confidence, spatial understanding, and knowledge (10-item multiple-choice questions). The analysis of nonparametric data utilized Wilcoxon signed-rank tests for within-group changes and Mann–Whitney tests for between-group differences. Results: Twenty-four medical students from 11 United Kingdom and Irish medical schools participated. Adherence was 100%, with all participants completing their assigned 10-minute intervention and all assessment points. Ninety-two percent of participants (n=22) reported no prior tracheostomy anatomy teaching. Additionally, 83% (n=20) had no prior remote-synchronized VR anatomy teaching experience. Anatomical confidence improved significantly in the VR group compared with animation (mean change 1.58, SD 1.00 vs mean 0.50, SD 0.80, =.01). Knowledge scores improved significantly in both groups (VR: mean 1.75, SD 1.54, =.007; animation: mean 2.83, SD 1.70, =.003), with no significant postintervention difference between groups (=.46). VR participants reported significantly superior spatial understanding across all measured domains (all ≤.009). These included depth perception (3.75 vs 2.58, =.009), appreciation of anatomy from different viewpoints (4.25 vs 2.33, =.001), mental reconstruction from varying angles (3.83 vs 2.08, =.002), and spatial depth supporting anatomical understanding (4.08 vs 2.08, =.001). Following the completion of both modalities, participants rated VR as more engaging (mean 4.54, SD 0.78) and more educationally effective (mean 4.29, SD 0.95) than animation. Conclusions: Remote VR teaching is feasible and engaging and enhances spatial understanding compared to animation. While knowledge gains were comparable between modalities, VR improved learner confidence and perceived 3D comprehension. Hence, VR may represent a scalable adjunct or alternative to traditional anatomy teaching.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/ea7ffabbe2afcc58142431a9a195eb32" />

STAT+: Eli Lilly tops prominent rankings on pharma R&D performance

Here’s one more sign of Eli Lilly’s dominance in the drug industry: It took both top spots in a prominent ranking of pharmaceutical innovators and investors.

The index, produced by U.K.-based IDEA Pharma, ranks drug company laboratories on two different sets of criteria: innovation, which takes into account revenue from new products, new drug approvals, and major drug development events; and invention, which looks at the number of drugs a company has in development, its clinical trials, and its R&D investment, among other factors. IDEA is part of SAI MedPartners, a larger consultancy. 

This is the first time that one company — in this case, Lilly — has ranked No. 1 in both categories.

Continue to STAT+ to read the full story…

Opinion: Britain embraces a Massachusetts experiment on tobacco regulation — just as the state might roll it back

The United Kingdom just adopted a tobacco-free generation law. Retailers can still sell tobacco to existing customers, but they will never be permitted to sell it to anyone born after Jan. 1, 2009.

In Massachusetts, 24 communities already use a similar “nicotine free generation” (NFG) birthdate phaseout of tobacco sales, including cigarettes, vapes, and pouches. What seemed to some an oddball local experiment here has become the leading edge of a public health revolution. Britain adds 69 million people to the 659,000 Massachusetts residents protected by this tobacco endgame.

Read the rest…

The Download: Musk v. Altman week 3, and Trump’s tech trading

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.

Musk v. Altman week 3: Musk and Altman traded blows over each other’s credibility. Now the jury will pick a side.

In the final week of the Musk v. Altman trial, lawyers attacked the credibility of the two tech leaders. Sam Altman was accused of lying and self-dealing, while Elon Musk was portrayed as a power-seeker trying to control artificial general intelligence.

The case unearthed new details about the two arch-rivals and OpenAI’s contested nonprofit status, as well as a golden trophy of a donkey’s ass awarded to an employee who challenged Musk.

Read the full story on the explosive final week of the trial.

—Michelle Kim

Michelle Kim, who’s also a lawyer, has been in court throughout the Musk v. Altman trial. Read her coverage of week 1 and week 2, plus a Q&A on what it was like in the room

The must-reads

I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.

1 Trump traded hundreds of millions in tech stocks before favorable policy moves
He bought shares in Nvidia, AMD, and Arm ahead of policy boosts. (Quartz)
+ And touted Palantir on Truth Social after buying its stock. (CNBC)
+ His crypto venture and Iran’s top exchange tapped the same networks. (Reuters $)

2 SpaceX plans to list on the Nasdaq stock exchange as soon as June 12
It wants to raise up to $75 billion at a $1.75 trillion valuation. (Reuters $)
+ BlackRock may invest up to $10 billion in the offering. (The Information $)
+ Cerebras’ blockbuster IPO has boosted hopes for the listing. (CNBC)
+ Which is set to dwarf many of the biggest IPOs on ⁠record. (Reuters)

3 Chinese AI groups have pulled ahead of US rivals in video generation
ByteDance and Kuaishou’s models lead in realism and scale. (FT $)
+ AI is fueling China’s short-drama boom. (MIT Technology Review)
+ While its AI labs are betting big on open source. (MIT Technology Review)

4 Iran says it will charge Big Tech for using undersea internet cables
The cables beneath the Strait of Hormuz carry vast digital traffic. (CNN)
+ Tech bosses met at Uber HQ on Saturday to discuss Iran’s future. (404 Media)

5 Samsung has a “last chance” to stop a massive strike over AI
Over 45,000 employees could walk out for 18 days this week. (CNBC
+ They want a bigger share of the AI boom. (FT $)
+ Samsung and its largest labor union will resume talks on Tuesday. (Reuters $)

6 Old oil and gas wells could become a new source of clean energy
US states plan to convert them into geothermal energy assets. (Wired $)
+ A balcony solar boom is coming to the US. (MIT Technology Review)

7 The ChatGPT era has triggered a 30% surge in grades at a top university
Grades inflated in text-heavy courses but remained flat in others. (Axios)
+ Princeton has changed its honor code because of AI cheating. (WSJ $)
+ And real cheating rates may be far higher. (The Times $)

8 Ex-Google CEO Eric Schmidt was fiercely booed during an AI speech
His graduation speech praising AI agents sparked uproar. (The Verge)
+ A populist backlash is building against AI. (MIT Technology Review)

9 Arm faces a US antitrust probe over its chip tech licenses
Regulators are investigating whether it has an illegal monopoly. (Bloomberg $)
+ Qualcomm has accused Arm of anticompetitive conduct. (Reuters $)

10 ArXiv will ban researchers who submit AI slop
Offending authors face year-long bans from the pre-print server. (TechCrunch)

Quote of the day

“When someone offers you a seat on the rocket ship, you do not ask which seat. You just get on.” 

—Ex-Google CEO Eric Schmidt extolls the virtues of AI agents in a graduation speech at the University of Arizona, prompting a chorus of boos.

One More Thing

a gloved hand holding up a microfluidic chip

WYSS INSTITUTE AT HARVARD UNIVERSITY


Is this the end of animal testing?

In a clean room in his lab, Sean Moore peers through a microscope at a bit of human intestinal tissue growing on a plastic chip. It’s one of 24 so-called “organs-on-chips” his team bought three years ago. The technology is designed to mimic human biology—and could reduce the need for animal testing.

The appeal is not only ethical. Around 95% of drugs developed through animal research ultimately fail in people, and early studies suggest organ-on-a-chip systems may offer more accurate insights into how diseases behave and how drugs work. But the field still faces major technical and cost challenges before it can replace animal research.

Find out how organ-on-chip technology could reshape drug testing.

—Harriet Brown

We can still have nice things

A place for comfort, fun, and distraction to brighten up your day. (Got any ideas? Drop me a line.)

+ Listen to the captivating first recordings of whale songs from 1949.
+ Meet the feline guardians of New York’s corner stores in this photo collection.
+ A newly discovered floor plan allowed historians to pinpoint the location of Shakespeare’s only property in London.
+ A music fan spent decades secretly recording 10,000 local shows. Now the entire collection is available online.

Organ-on-Chip Method Designed to Zero In on Connection Between Diabetes and Dementia

A University of Bath-led research effort received £500,000 to develop an organ-on-chip device that replicates connections between the brain, gut, and pancreas. The GlucoBrain project is designed to allow researchers to track how signals move between the organs and uncover why diabetes may lead to changes in memory and cognition.

Collaborators include investigators from the University of Oxford and Johns Hopkins. Their findings could pave the way for new treatments to improve the lives of millions of people affected by diabetes, dementia, or both, notes the team.

Diabetes and Alzheimer’s disease are two of the world’s most pressing health problems, especially in aging societies. While diabetes is widely known to affect the heart, kidneys, and eyes, growing evidence suggests it is also linked with problems in memory, learning, and brain function. However, the biological mechanisms behind this link remain poorly understood.

“Our gut, pancreas, and brain are constantly communicating via a network of signals, helping us regulate hunger and blood sugar,”  says Despina Moschou, PhD, project lead. “But we still don’t fully understand how these signals interact at a cellular level and why glucose levels are linked to cognitive decline. “By creating a connected system on a chip, we can study in real time how signals travel between organs, how diabetes may impair brain function, and how new drugs could help.”

Most current knowledge on the link between diabetes and dementia comes from animal studies, simple cell cultures, and patient studies. While these are useful, they don’t fully and accurately capture all the complex interactions between our organs, hormones, and cells, points out Moschou.

Organ-on-chip technology uses living human cells in miniature devices that mimic how organs work in the body. Unlike cell cultures grown in a petri dish, these devices allow cells to grow in three dimensions, receive a controlled supply of nutrients and interact more naturally. Researchers will also be able to isolate these individual organs and cell types to understand exactly how they communicate at a molecular level.

The three-year project starts in October, bringing together engineers, clinicians, biologists and computer scientists to model the complex disease interactions. The team will first develop individual chip models for the gut, pancreas, and brain, before connecting them into a multi-organ system. They will gradually increase complexity and measure how each organ responds to glucose, hormones and different drug treatments.

Researchers from the University of Oxford will provide core clinical expertise in diabetes and metabolic disease, ensuring models are physiologically accurate. The team from Johns Hopkins University brings specialist expertise in Alzheimer’s disease and brain organoids.

GlucoBrain is a pilot project established to help researchers understand exactly how diseases like diabetes and dementia work at a deeper, biological level. This early-stage research will build the foundations for even more advanced and realistic models, bringing together more organs and cell types, explain team members. By harnessing the power of artificial intelligence, the devices have the potential to reveal new insights into how diseases emerge and develop.

“Not only would these devices give us an unprecedented way to study diseases, but they could help speed up drug discovery and testing, reducing reliance on animal models and making results more relevant to humans,” continues Moschou. “In the long term, they could pave the way for personalized medicine, using a patient’s own cells to identify the most effective treatment.”

The project is funded by the Engineering and Physical Sciences Research Council (EPSRC) Health Technologies Connectivity Awards.

 

The post Organ-on-Chip Method Designed to Zero In on Connection Between Diabetes and Dementia appeared first on GEN – Genetic Engineering and Biotechnology News.

Microbiome Therapy Could Help Drug-Resistant Melanoma Patients

Microbiotica, a microbiome-focused biotech based in Cambridge in the U.K., has achieved good Phase Ib results in a trial of its microbiome therapy for patients with advanced melanoma skin cancer.

The therapy, currently known as MB097, is designed to be given to patients who have not previously responded to immunotherapy in addition to a checkpoint inhibitor pembrolizumab. MB097 was developed to reverse the drug resistance seen in these patients and is based on research looking into the gut microbiome of melanoma patients who do respond to this kind of immunotherapy.

The primary endpoint of the trial, which included 41 patients from the U.K., France, Italy, and Spain, who had previously shown resistance to anti-PD-1 drugs, was safety and tolerability of MB097. Several secondary endpoints including response rate, duration of response, and overall survival were also included. The therapy, which contains nine beneficial strains of gut bacteria, met both its primary and secondary endpoints in the study, according to the company, although precise details will be released at a scientific conference later this year.

“There is increasing evidence that the microbiome plays a crucial role in patients’ response to immune checkpoint inhibitors. Clinical benefit has been reported with fecal microbiota transplantations, while MB097 capsules taken orally each day affords an easy and reproducible way of modifying the microbiome,” said the national coordinating investigator for the study, Pippa Corrie, MD, PhD, a clinician and researcher from Cambridge University Hospitals NHS Foundation Trust, in a press statement.

“The MELODY-1 study results show that MB097 is well tolerated, with encouraging early signs of efficacy in a very difficult to treat metastatic melanoma patient population with primary resistance to anti-PD-1 based immunotherapy, in whom there is a significant unmet need.”

Up to half of all advanced melanoma patients fail to respond to anti-PD-1 immunotherapy, leaving them with very few options. A growing body of research, including a 2021 study showing fecal transplant can overcome resistance to anti-PD-1 immunotherapy, shows that the gut microbiome plays an important role in whether a patient’s immune system mounts an effective anti-tumor response when given these therapies.

The make-up of MB097 is based on detailed research looking at strains of bacteria linked to effective response to immunotherapy. Preclinical work showed that the bacteria in the therapy directly activate cytotoxic T cells and counter immunosuppressive tumor macrophages. If larger controlled trials confirm these initial results MB097 could become a standard add-on to immunotherapy.

Microbiotica has another clinical program in ulcerative colitis, which also reported good results earlier this year in another Phase Ib trial. In total, 63% of those in the treatment group achieved clinical disease remission versus 30% in the placebo group and all were also taking standard therapy for the autoimmune disease.

The company now plans to move both its programs to larger controlled studies with a view to moving closer to market approval with both therapies.

The post Microbiome Therapy Could Help Drug-Resistant Melanoma Patients appeared first on Inside Precision Medicine.